Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
Rhea-AI Summary
Iovance Biotherapeutics (NASDAQ: IOVA) will report fourth quarter and full year 2025 financial results and provide corporate updates via a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET.
According to the company, the live and archived webcast will be available on the Investors section of its website and the archived webcast will remain accessible for one year.
Positive
- None.
Negative
- None.
News Market Reaction – IOVA
In the Feb 12 session, IOVA declined 3.08%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Clinical data update | Positive | -3.3% | Real‑world Amtagvi data showing strong response and disease control rates. |
| Jan 16 | Inducement grants | Neutral | +3.4% | Stock option inducement grants to new non‑executive employees. |
| Dec 19 | Inducement grants | Neutral | +12.1% | Additional option grants to new employees under inducement plan. |
| Nov 21 | Inducement grants | Neutral | +11.6% | Larger batch of inducement stock options for new hires. |
| Nov 06 | Earnings and update | Positive | +27.6% | Q3 2025 results with growing product revenue and reaffirmed guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mostly aligned reactions, with strong positive moves on favorable earnings and routine equity updates, but one instance where positive clinical data was followed by a negative price reaction.
Over the last several months, Iovance has balanced commercial, clinical, and corporate developments. A Q3 2025 update with growing revenue and guidance reaffirmation saw a strong positive reaction. Multiple inducement option grants in Nov–Dec 2025 drew modest to solid gains, indicating comfort with routine equity compensation. In contrast, encouraging real‑world Amtagvi data on Feb 5, 2026 coincided with a price decline, showing that positive clinical news has not always translated into immediate upside. Today’s earnings date announcement fits into this cadence of scheduled updates.
Key Terms
tumor infiltrating lymphocyte (TIL) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates.
To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/5rbo34au. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
